Technical Analysis for ABVC - ABVC Biopharma, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 1.11 | 4.72% | 0.05 |
Earnings due: May 13
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Wide Bands | Range Expansion | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
NR7 | Range Contraction | 4.72% | |
NR7-2 | Range Contraction | 4.72% | |
Narrow Range Bar | Range Contraction | 4.72% | |
Stochastic Reached Oversold | Weakness | 4.72% | |
Wide Bands | Range Expansion | 4.72% | |
Oversold Stochastic | Weakness | 4.72% | |
MACD Bearish Centerline Cross | Bearish | 2.78% | |
Hammer Candlestick | Bullish | 2.78% |
Alert | Time |
---|---|
Down 1% | about 17 hours ago |
Rose Above Previous Day's High | about 18 hours ago |
Up 2% | about 18 hours ago |
Up 1% | about 18 hours ago |
Possible NR7 | 1 day ago |
Get a Trading Assistant
- Earnings date: 05/13/2024
ABVC Biopharma, Inc. Description
American BriVision (Holding) Corporation, a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, a combination therapy for triple negative breast cancer; ABV-1504 for major depressive disorders; ABV-1505 for attention deficit hyperactivity disorder; ABV-1703 for the treatment of pancreatic cancer; ABV-1702 to treat myelodysplastic syndromes; ABV-1601 for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company was incorporated in 2015 and is based in Fremont, California. American BriVision (Holding) Corporation is a subsidiary of YuanGene Corporation.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Pancreatic Cancer Depression Major Depressive Disorder Myelodysplastic Syndrome Attention Deficit Hyperactivity Disorder Treatment Of Pancreatic Cancer Triple Negative Breast Cancer
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 8.85 |
52 Week Low | 0.697 |
Average Volume | 1,362,692 |
200-Day Moving Average | 1.37 |
50-Day Moving Average | 1.20 |
20-Day Moving Average | 1.18 |
10-Day Moving Average | 1.23 |
Average True Range | 0.13 |
RSI (14) | 45.05 |
ADX | 18.96 |
+DI | 26.53 |
-DI | 23.08 |
Chandelier Exit (Long, 3 ATRs) | 1.35 |
Chandelier Exit (Short, 3 ATRs) | 1.32 |
Upper Bollinger Bands | 1.52 |
Lower Bollinger Band | 0.85 |
Percent B (%b) | 0.39 |
BandWidth | 56.58 |
MACD Line | -0.02 |
MACD Signal Line | 0.00 |
MACD Histogram | -0.0223 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 1.25 | ||||
Resistance 3 (R3) | 1.24 | 1.18 | 1.22 | ||
Resistance 2 (R2) | 1.18 | 1.15 | 1.19 | 1.21 | |
Resistance 1 (R1) | 1.15 | 1.13 | 1.17 | 1.16 | 1.21 |
Pivot Point | 1.09 | 1.09 | 1.10 | 1.10 | 1.09 |
Support 1 (S1) | 1.06 | 1.06 | 1.08 | 1.07 | 1.01 |
Support 2 (S2) | 1.00 | 1.04 | 1.01 | 1.01 | |
Support 3 (S3) | 0.97 | 1.00 | 1.00 | ||
Support 4 (S4) | 0.98 |